ExeVir
Viki Bockstal is the Chief Scientific Officer at ExeVir since April 2021. Prior to this role, Viki held the position of Biomarker Lead Filovirus Vaccines at The Janssen Pharmaceutical Companies of Johnson & Johnson from November 2012 to March 2021. Viki has a background in Bioengineering Sciences and Immunology, with a PhD from Vrije Universiteit Brussel. Viki has a wealth of experience in preclinical development, leading various vaccine programs and playing key roles in the immunology strategy for Ebola and Filovirus vaccines.
ExeVir
Rapid viral control in a world that needs it. ExeVir develops single-domain antibody-based therapies that help patients ward off viral infections. Our lead drug candidate is in accelerated development as a COVID-19 therapeutic.